PRITHVIRAJ BOSE to Leukemia, Lymphocytic, Chronic, B-Cell
This is a "connection" page, showing publications PRITHVIRAJ BOSE has written about Leukemia, Lymphocytic, Chronic, B-Cell.
Connection Strength
1.679
-
An update on the efficacy of Venetoclax for chronic lymphocytic leukemia. Expert Opin Pharmacother. 2023 May-Aug; 24(11):1307-1316.
Score: 0.365
-
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma. 2019 07; 60(7):1603-1605.
Score: 0.271
-
Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. 2023 07; 37(7):1444-1453.
Score: 0.091
-
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855.
Score: 0.085
-
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
Score: 0.080
-
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
Score: 0.079
-
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085.
Score: 0.071
-
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4.
Score: 0.070
-
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318.
Score: 0.069
-
Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
Score: 0.069
-
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864.
Score: 0.068
-
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
Score: 0.066
-
Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother. 2017 Jun; 18(9):857-873.
Score: 0.060
-
Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017 09; 58(9):1-17.
Score: 0.059
-
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618.
Score: 0.059
-
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma. 2017 06; 58(6):1349-1357.
Score: 0.059
-
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.
Score: 0.059